These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2226671)

  • 1. The concept and treatment of osteoporosis.
    Rittinghaus EF; Hesch RD; Harms HM; Busch U; Prokop M; Delling G
    Exp Gerontol; 1990; 25(3-4):357-65. PubMed ID: 2226671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcitonin therapy in osteoporosis.
    Muñoz-Torres M; Alonso G; Raya MP
    Treat Endocrinol; 2004; 3(2):117-32. PubMed ID: 15743107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy.
    Peichl P; Rintelen B; Kumpan W; Bröll H
    Gynecol Endocrinol; 1999 Feb; 13(1):7-14. PubMed ID: 10368793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis.
    Siminoski K; Josse RG
    CMAJ; 1996 Oct; 155(7):962-5. PubMed ID: 8837547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
    Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
    Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.
    Schacht E; Richy F; Reginster JY
    J Musculoskelet Neuronal Interact; 2005; 5(3):273-84. PubMed ID: 16172518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.
    Rico H; Revilla M; Hernández ER; Villa LF; Alvarez de Buergo M
    Calcif Tissue Int; 1995 Mar; 56(3):181-5. PubMed ID: 7750020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study.
    Ebeling PR; Wark JD; Yeung S; Poon C; Salehi N; Nicholson GC; Kotowicz MA
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4098-103. PubMed ID: 11549632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcitonin.
    Silverman SL
    Am J Med Sci; 1997 Jan; 313(1):13-6. PubMed ID: 9001161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.
    Overgaard K; Hansen MA; Jensen SB; Christiansen C
    BMJ; 1992 Sep; 305(6853):556-61. PubMed ID: 1393035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of osteoporosis. Antiresorptive therapy.
    Miller PD
    Clin Lab Med; 2000 Sep; 20(3):603-22, viii. PubMed ID: 10986624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study.
    Tóth E; Csupor E; Mészáros S; Ferencz V; Németh L; McCloskey EV; Horváth C
    Bone; 2005 Jan; 36(1):47-51. PubMed ID: 15664001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
    J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Present and future of osteoporosis therapy.
    Seeman E; Tsalamandris C; Bass S; Pearce G
    Bone; 1995 Aug; 17(2 Suppl):23S-29S. PubMed ID: 8579894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.
    Plosker GL; McTavish D
    Drugs Aging; 1996 May; 8(5):378-400. PubMed ID: 8935399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salmon calcitonin and calcium in the treatment of male osteoporosis: the effect on bone mineral density.
    Erlacher L; Kettenbach J; Kiener H; Graninger W; Kainberger F; Pietschmann P
    Wien Klin Wochenschr; 1997 Apr; 109(8):270-4. PubMed ID: 9163888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of calcitonin and vitamin D in osteoporosis.
    Palmieri GM; Pitcock JA; Brown P; Karas JG; Roen LJ
    Calcif Tissue Int; 1989 Sep; 45(3):137-41. PubMed ID: 2505903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of parathyroid hormone on cancellous bone mass and structure in osteoporosis.
    Miyakoshi N
    Curr Pharm Des; 2004; 10(21):2615-27. PubMed ID: 15320749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcitonin and calcium combined therapy in osteoporosis: effects on vertebra trabecular bone density.
    Ozoran K; Paker N; Başgöze O; Hasçelik Z; Erzen C; Narman S; Ozker R
    J Int Med Res; 1989; 17(4):395-400. PubMed ID: 2792558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.